賽倫生物(688163.SH):公司現有的四種抗蛇毒血清產品可以覆蓋我國絕大部分常見毒蛇種類
格隆匯7月4日丨有投資者向賽倫生物(688163.SH)提問:公司抗蛇毒血清產品能否覆蓋所有的毒蛇咬傷治療?
賽倫生物回覆:對於毒蛇咬傷救治中抗蛇毒血清的使用秉承“同種專一、異種聯合”的原則。即,同種毒素類型的蛇咬傷,選擇高特異性的同種抗蛇毒血清,可取得顯而易見的效果;對於無特異性抗蛇毒血清的毒蛇咬傷,可聯合使用同類或相似毒性的抗蛇毒血清進行治療,能有效中和毒素,取得良好的治療效果,治療中較常規劑量一般加大使用劑量。其他罕見毒蛇咬傷也能根據“異種聯合”原則進行治療。
因此,公司現有的四種抗蛇毒血清產品可以覆蓋我國絕大部分常見毒蛇種類。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.